Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II, Double-blind, Placebo-Controlled, Randomized Trial Examining Natrunix in Combination With Methotrexate (+Folate) for the Treatment of Rheumatoid Arthritis

NCT05363891 is registered in ClinicalTrials.gov with XBiotech, Inc. as lead sponsor.

NCT NCT05363891
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05363891 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II, Double-blind, Placebo-Controlled, Randomized Trial Examining Natrunix in Combination With Methotrexate (+Folate) for the Treatment of Rheumatoid Arthritis
Lead sponsor
XBiotech, Inc.
Phase
Phase 2
Overall status
Completed
Start date
August 8, 2023
Completion date
October 31, 2024
Enrollment
243 (actual)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis